세계의 피부과 CRO 시장 : 시장 규모, 점유율 및 동향 분석(유형별, 서비스별, 지역별), 부문별 예측(2025-2033년)

Dermatology CRO Market Summary

The global dermatology CRO market size was estimated at USD 5.42 billion in 2024 and is projected to reach USD 9.09 billion by 2033, growing at a CAGR of 5.80% from 2025 to 2033. The dermatology contract research organization (CRO) market is experiencing robust growth, primarily driven by the rising prevalence of chronic skin conditions such as psoriasis, eczema, acne, and skin cancers across the globe.

Besides, growing interest of dermatological companies and increasing awareness of dermatological health, coupled with the expansion of the biopharmaceutical pipeline for innovative topical and systemic therapies is further driving the demand for specialized clinical research services. In addition, factors such as growing investments in dermatology R&D, the rising adoption of personalized medicine, and enhanced patient participation facilitated by digital tools are expected to support the market growth.

Moreover, the emerging trends such as decentralized clinical trials, tele dermatology, and AI-powered skin imaging are reshaping the dermatology clinical trial landscape, improving patient access and data accuracy. The increased use of wearable skin sensors and advanced imaging technologies is further enhancing real-time monitoring and endpoint assessment. Overall, the market scenario is favorable due to rising government initiatives supporting dermatology research, expanding applications in cosmetic dermatology, and increased clinical trial activity in emerging regions like Asia-Pacific and Latin America.

Furthermore, the CROs are taking strategic initiatives such as expanding their geographic presence, forming partnerships with technology providers, and investing in integrated digital platforms to offer comprehensive dermatology trial solutions. In addition, technology advancements, including AI and machine learning for lesion analysis, decentralized trial platforms, and the integration of real-world data, enable CROs to enhance trial efficiency, patient engagement, and data quality, strengthening their competitive position in this dynamic market.

Global Dermatology CRO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dermatology CRO market report based on type, service, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead optimization
• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Project Management/Clinical Supply Management
• Data Management
• Regulatory/Medical Affairs
• Medical Writing
• Clinical Monitoring
• Quality Management/ Assurance
• Bio-statistics
• Investigator Payments
• Laboratory
• Patient and Site Recruitment
• Technology
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Argentina
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Service
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Value-Chain-Based Sizing & Forecasting
  • 1.7.3. Multivariate Model Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Dermatology CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Chronic and Complex Skin Disorders
    • 3.2.1.2. Increasing Adoption of Advanced Technologies
    • 3.2.1.3. Growing Demand for Aesthetic Dermatology and Cosmeceuticals
    • 3.2.1.4. Increasing Outsourcing of R&D Activities
    • 3.2.1.5. Favorable Environment for Clinical Trials in Developing Countries
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality Issues of CRO Services
    • 3.2.2.2. Intellectual Property Rights Issues
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Dermatology CRO Market: Type Estimates & Trend Analysis

• 4.1. Dermatology CRO Market, By Type: Segment Dashboard
• 4.2. Dermatology CRO Market, By Type: Movement Analysis
• 4.3. Dermatology CRO Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Phase I
    • 4.6.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Phase II
    • 4.6.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Phase III
    • 4.6.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Phase IV
    • 4.6.5.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Dermatology CRO Market: Service Estimates & Trend Analysis

• 5.1. Dermatology CRO Market, By Service: Segment Dashboard
• 5.2. Dermatology CRO Market, By Service: Movement Analysis
• 5.3. Dermatology CRO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Project Management/Clinical Supply Management
  • 5.4.1. Project Management/Clinical Supply Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Data Management
  • 5.5.1. Data Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Regulatory/Medical Affairs
  • 5.6.1. Regulatory/Medical Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Medical Writing
  • 5.7.1. Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Clinical Monitoring
  • 5.8.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Quality Management/ Assurance
  • 5.9.1. Quality Management/ Assurance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Bio-statistics
  • 5.10.1. Bio-statistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Investigator Payments
  • 5.11.1. Investigator Payments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Laboratory
  • 5.12.1. Laboratory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.13. Patient and Site Recruitment
  • 5.13.1. Patient and Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.14. Technology
  • 5.14.1. Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.15. Others
  • 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Dermatology CRO Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2033
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Australia
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
  • 7.1.1. Market Leaders
  • 7.1.2. Emerging Players
• 7.2. Company Market Share/Assessment Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. IQVIA Inc.
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Service Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Labcorp Drug Development
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Service Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Thermo Fisher Scientific Inc. (PPD)
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Service Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Parexel International Corp.
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Service Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Charles River Laboratories
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Service Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. ICON, Plc
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Service Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Syneos Health
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Service Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Pharmaron
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Service Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Aragen Life Sciences Ltd.
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Service Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Wuxi AppTec
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Service Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. MEDPACE
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Service Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. CTI Clinical Trial & Consulting
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Service Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Bioskin
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Service Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Proinnovera GmbH
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Service Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Biorasi, LLC
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Service Benchmarking
    • 7.3.15.4. Strategic Initiatives